Jazz Pharmaceuticals PLC
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $134.82
- Today's High:
- $136.855
- Open Price:
- $136.33
- 52W Low:
- $120.64
- 52W High:
- $160.96
- Prev. Close:
- $136.46
- Volume:
- 419799
Company Statistics
- Market Cap.:
- $8.62 billion
- Book Value:
- 55.612
- Revenue TTM:
- $3.76 billion
- Operating Margin TTM:
- 26.8%
- Gross Profit TTM:
- $3.39 billion
- Profit Margin:
- -2.3%
- Return on Assets TTM:
- 5.61%
- Return on Equity TTM:
- -2.57%
Company Profile
Jazz Pharmaceuticals PLC had its IPO on 2007-06-01 under the ticker symbol JAZZ.
The company operates in the Healthcare sector and Biotechnology industry. Jazz Pharmaceuticals PLC has a staff strength of 2,800 employees.
Stock update
Shares of Jazz Pharmaceuticals PLC opened at $136.33 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $134.82 - $136.86, and closed at $135.72.
This is a -0.54% slip from the previous day's closing price.
A total volume of 419,799 shares were traded at the close of the day’s session.
In the last one week, shares of Jazz Pharmaceuticals PLC have slipped by -5.59%.
Jazz Pharmaceuticals PLC's Key Ratios
Jazz Pharmaceuticals PLC has a market cap of $8.62 billion, indicating a price to book ratio of 3.6126 and a price to sales ratio of 2.6873.
In the last 12-months Jazz Pharmaceuticals PLC’s revenue was $3.76 billion with a gross profit of $3.39 billion and an EBITDA of $1.62 billion. The EBITDA ratio measures Jazz Pharmaceuticals PLC's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Jazz Pharmaceuticals PLC’s operating margin was 26.8% while its return on assets stood at 5.61% with a return of equity of -2.57%.
In Q2, Jazz Pharmaceuticals PLC’s quarterly earnings growth was a positive 175.7% while revenue growth was a positive 2.6%.
Jazz Pharmaceuticals PLC’s PE and PEG Ratio
- Forward PE
- 9.1075
- Trailing PE
- 0
- PEG
- 3.9942
Its diluted EPS in the last 12-months stands at $-1.61 per share while it has a forward price to earnings multiple of 9.1075 and a PEG multiple of 3.9942. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Jazz Pharmaceuticals PLC’s profitability.
Jazz Pharmaceuticals PLC stock is trading at a EV to sales ratio of 4.1386 and a EV to EBITDA ratio of 16.962. Its price to sales ratio in the trailing 12-months stood at 2.6873.
Jazz Pharmaceuticals PLC stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $11.26 billion
- Total Liabilities
- $945.27 million
- Operating Cash Flow
- $-85739000.00
- Capital Expenditure
- $5.74 million
- Dividend Payout Ratio
- 0%
Jazz Pharmaceuticals PLC ended 2024 with $11.26 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $11.26 billion while shareholder equity stood at $3.53 billion.
Jazz Pharmaceuticals PLC ended 2024 with $910.72 million in deferred long-term liabilities, $945.27 million in other current liabilities, 61000.00 in common stock, $811.85 million in retained earnings and $1.74 billion in goodwill. Its cash balance stood at $1.28 billion and cash and short-term investments were $1.36 billion. The company’s total short-term debt was $47,982,000 while long-term debt stood at $5.69 billion.
Jazz Pharmaceuticals PLC’s total current assets stands at $3.01 billion while long-term investments were $0 and short-term investments were $80.00 million. Its net receivables were $610.39 million compared to accounts payable of $98.43 million and inventory worth $657.21 million.
In 2024, Jazz Pharmaceuticals PLC's operating cash flow was $-85739000.00 while its capital expenditure stood at $5.74 million.
Comparatively, Jazz Pharmaceuticals PLC paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $135.72
- 52-Week High
- $160.96
- 52-Week Low
- $120.64
- Analyst Target Price
- $201.2
Jazz Pharmaceuticals PLC stock is currently trading at $135.72 per share. It touched a 52-week high of $160.96 and a 52-week low of $160.96. Analysts tracking the stock have a 12-month average target price of $201.2.
Its 50-day moving average was $133.49 and 200-day moving average was $141.1 The short ratio stood at 5.92 indicating a short percent outstanding of 0%.
Around 257.7% of the company’s stock are held by insiders while 9390.3% are held by institutions.
Frequently Asked Questions About Jazz Pharmaceuticals PLC
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, such as hematologic and solid tumors. Its lead marketed products in neuroscience include Xywav, an oral solution for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy and idiopathic hypersomnia (IH); Xyrem, a sodium oxybate oral solution for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older; and Epidiolex, a cannabidiol oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients one year of age or older. The company’s lead marketed products in oncology comprise Zepzelca for the treatment of adult patients with metastatic small cell lung cancer; Rylaze, a product for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adults and pediatric patients aged one month or older who has developed hypersensitivity to E. coli-derived asparaginase; Vyxeos, a liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem cell transplantation. It has licensing and collaboration agreements with Zymeworks Inc.; Sumitomo Pharma Co., Ltd; Werewolf Therapeutics, Inc.; Codiak BioSciences, Inc.; Ligand Pharmaceuticals Incorporated; XL-protein GmbH; and Redx Pharma plc. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.